Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 64Neoplasms 8Sarcoma 6Ovarian Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Sarcoma, Ewing 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Rhabdomyosarcoma 3Rhabdoid Tumor 3Prostatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma 3Liposarcoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

Gemcitabine 5Nivolumab 3Irinotecan 3Ipilimumab 3Docetaxel 3Cyclophosphamide 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3pegfilgrastim 2Vincristine 2Temozolomide 2Ibandronic Acid 2Everolimus 2Doxorubicin 2CTLA-4 Antigen 2spartalizumab 1saracatinib 1samarium Sm-153 lexidronam 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1anlotinib 1angiotensin I (1-7) 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Topotecan 1Taxes 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Neoplasms × palbociclib × Clear all
NCT03709680 2025-01-14

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Pfizer

Phase 2 Active not recruiting
128 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Bone Neoplasms, Medulloblastoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡